• Users Online: 220
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2022  |  Volume : 17  |  Issue : 4  |  Page : 1028

Serum BDNF in COVID-19 Patients: A Summative Analysis

1 Private Academic Practice, Bangkok, Thailand
2 Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India

Date of Submission21-Mar-2021
Date of Decision10-Dec-2021
Date of Acceptance16-Dec-2021
Date of Web Publication10-Feb-2023

Correspondence Address:
Dr. Beuy Joob
Private Academic Practice, Bangkok, Thailand, 13 Academic Center, Bangkok 112
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdmimsu.jdmimsu_121_21

Rights and Permissions

How to cite this article:
Joob B, Wiwanitkit V. Serum BDNF in COVID-19 Patients: A Summative Analysis. J Datta Meghe Inst Med Sci Univ 2022;17:1028

How to cite this URL:
Joob B, Wiwanitkit V. Serum BDNF in COVID-19 Patients: A Summative Analysis. J Datta Meghe Inst Med Sci Univ [serial online] 2022 [cited 2023 Mar 28];17:1028. Available from: http://www.journaldmims.com/text.asp?2022/17/4/1028/369473


The COVID-19 is a new coronavirus infection. This infection causes pandemic and results in a worldwide public health problem. The infection manifests as an acute respiratory illness. However, it can also manifest atypical clinical presentation.[1] The neuropsychiatric problem due to COVID-19 is also possible. The pathophysiological process relating to the angiotensin-converting enzyme 2\Mas\BDNF signaling pathway is mentioned.[2] Alteration of serum DNF in COVID-19 patients is an interesting issue in laboratory medicine.[2] There are few reports on serum BDNF determination in COVID-19 patients.[3],[4]

Here, the authors perform a summative analysis for reappraisal on those available data on serum BDNF in COVID-19 patients. From 10 COVID-19 patients (five males and five females; age 7–90 years with average 52.5 ± 18.6 years), the average serum BDNF level is 5265.69 ± 2089.50 pg/mL. Comparing this level to the level in the normal population (range = 32690 ± 8330 pg/mL), the value in COVID-19 is lower. This can confirm the hypothesis that there might be downregulation and decreased expression of BDNF in COVID-19.[2] Further studies on the BDNF level in COVID-19 in a larger sample size and the assessment of clinical association are recommended.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Tin SS, Wiwanitkit V. Uncommon atypical presentations of COVID-19: Important and should not be under recognized! J Health Sci Med Res 2020;38:153-8.  Back to cited text no. 1
Motaghinejad M, Gholami M. Possible neurological and mental outcomes of COVID-19 infection: A hypothetical role of ACE-2\Mas\BDNF signaling pathway. Int J Prev Med 2020;11:84.  Back to cited text no. 2
  [Full text]  
Azoulay D, Shehadeh M, Chepa S, Shaoul E, Baroum M, Horowitz NA, et al. Recovery from SARS-CoV-2 infection is associated with serum BDNF restoration. J Infect 2020;81:e79-81.  Back to cited text no. 3
De Paulis M, Oliveira DB, Vieira RP, Pinto IC, Machado RR, Cavalcanti MP, et al. Multisystem inflammatory syndrome associated with COVID-19 with neurologic manifestations in a child: A brief report. Pediatr Infect Dis J 2020;39:e321-4.  Back to cited text no. 4


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal